

Henry S H Chan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2469473/publications.pdf>

Version: 2024-02-01

24
papers

207
citations

1163117

8
h-index

1058476

14
g-index

24
all docs

24
docs citations

24
times ranked

253
citing authors

#	ARTICLE	IF	CITATIONS
1	The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 6323-6332.	7.0	42
2	Current Review on High-Risk Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 96-108.	2.3	24
3	A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. <i>Pathology</i> , 2020, 52, 167-178.	0.6	23
4	SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2021, 138, 396-396.	1.4	22
5	Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial. <i>Blood</i> , 2020, 136, 11-12.	1.4	19
6	Impact of age, sex, ethnicity, socio-economic deprivation and novel pharmaceuticals on the overall survival of patients with multiple myeloma in New Zealand. <i>British Journal of Haematology</i> , 2020, 188, 692-700.	2.5	13
7	Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial. <i>Blood</i> , 2020, 136, 28-30.	1.4	13
8	Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBORd with or without thalidomide-based consolidation: a retrospective multi-centre analysis of real-world data. <i>British Journal of Haematology</i> , 2019, 187, 470-477.	2.5	12
9	Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma. <i>Blood Advances</i> , 2022, 6, 3472-3479.	5.2	12
10	Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 225-234.	0.4	7
11	ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma. <i>Blood</i> , 2019, 134, 5244-5244.	1.4	4
12	Retrospective Analysis of the Effectiveness of a Reduced Dose of Idarucizumab in Dabigatran Reversal. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1096-1103.	3.4	4
13	Significance of treatment response when managing patients with primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 349-357.	1.3	3
14	Fixed-dose three-factor prothrombin complex concentrates is safe and effective in warfarin reversal. <i>Internal Medicine Journal</i> , 2021, 51, 1884-1890.	0.8	2
15	Electronic FRAIL score may predict treatment outcomes in older adults with myeloma. <i>Journal of Geriatric Oncology</i> , 2021, 12, 515-520.	1.0	2
16	Single Centre Experience in Treating Elderly Patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndrome with a Combination of Low Dose Cytarabine, Venetoclax and Fluconazole (VeLDAC-F). <i>Blood</i> , 2018, 132, 5220-5220.	1.4	2
17	Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. <i>Internal Medicine Journal</i> , 2021, 51, 1707-1712.	0.8	1
18	Fixed Dose Carfilzomib Triplets in Lenalidomide Refractory Myeloma. <i>Blood</i> , 2018, 132, 3306-3306.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Electronic FRAIL score as a predictor of treatment outcomes in older patients with diffuse large B-cell lymphoma. <i>Journal of Geriatric Oncology</i> , 2022, 13, 505-510.	1.0	1
20	Efficacy and Tolerability of Gemcitabine-Based Chemotherapy in Relapsed/Refractory Lymphoma Patients Not Eligible for Stem Cell Transplant. <i>Blood</i> , 2021, 138, 4566-4566.	1.4	0
21	Epidemiology of Acute Myeloid Leukaemia in New Zealand: A National Cancer Registry Analysis. <i>Blood</i> , 2020, 136, 36-37.	1.4	0
22	Conservative Management of Hemochromatosis without Long-Term Maintenance Venesections in Patients with Moderate Iron Burden. <i>Blood</i> , 2020, 136, 44-45.	1.4	0
23	Bortezomib Induction and Consolidation in Patients with Multiple Myeloma Who Received Frontline Autologous Stem Cell Transplant. <i>Blood</i> , 2020, 136, 33-33.	1.4	0
24	Māori and Pacific peoples with multiple myeloma in New Zealand are younger and have inferior survival compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.4	0